News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Abbott Japan and Eisai Company, Ltd. (ESALY.PK) Receive Approval to Market the Pancreatic Digestive Enzyme Replacement Drug Lipacreon(R) (pancrelipase) in Japan


4/22/2011 10:48:24 AM

Tokyo, Apr 22, 2011 (JCN Newswire) - Abbott Japan Co., Ltd. and Eisai Co., Ltd. (TSE: 4523) announced today that they have received approval to market the pancreatic enzyme replacement drug Lipacreon(R)(pancrelipase) in Japan as a pancreatic digestive enzyme replacement in patients with pancreatic exocrine insufficiency (PEI). While Abbott Japan is the marketing authorization holder of Lipacreon, Eisai intends to sell the drug once it is listed on the National Health Insurance (NHI) price list.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES